Bioactive nucleoside analogues possessing selected five-membered azaheterocyclic bases

European Journal of Medicinal Chemistry

Volumn 97, Issue 1, 2015, Pages 409-418

  Zeidler, Joanna ^a   Baraniak, Dagmara ^a   Ostrowski, Tomasz ^a  

^a POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

1,2,3 Triazole nucleosides; 1,2,4 Triazole nucleosides; Imidazole nucleosides; Mechanism of action; Ribavirin

Indexed keywords

1,2,3 TRIAZOLE 4 CARBOXAMIDE; 1,2,4 TRIAZOLE 3 CARBOXAMIDE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; AGLYCONE; AMIDE; IMIDAZOLE 4 CARBOXAMIDE; MIZORIBINE; NUCLEOSIDE ANALOG; RIBAVIRIN; UNCLASSIFIED DRUG; HETEROCYCLIC COMPOUND; NUCLEOSIDE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CANCER INHIBITION; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; NONHUMAN; REVIEW; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; AZA COMPOUNDS; HETEROCYCLIC COMPOUNDS; HUMANS; MOLECULAR STRUCTURE; NUCLEOSIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85057444720     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. B.G. Drew, B.A. Kingwell, Acadesine, an adenosine-regulating agent with the potential for widespread indications, Expert Opin. Pharmacother. 9 (2008) 2137-2144 (and ref. therein).
2. M.F. Vincent, M.D. Erion, H.E. Gruber, G. Van den Berghe, Hypoglycaemic effect of AICAriboside in mice, Diabetologia 39 (1996) 1148-1155.
3. J.M. Corton, J.G. Gillespie, S.A. Hawley, D.G. Hardie, 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMPactivated protein kinase in intact cells? Eur. J. Biochem. 229 (1995) 558-565.
4. R. Bergeron, S.F. Previs, G.W. Cline, P. Perret, R.R. Russell III, L.H. Young, G.I. Shulman, Effect of 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats, Diabetes 50 (2001) 1076-1082.
5. H. Boon, M. Bosselaar, S.F.E. Praet, E.E. Blaak, W.H.M. Saris, A.J.M. Wagenmakers, S.L. McGee, C.J. Tack, P. Smits, M. Hargreaves, L.J.C. van Loon, Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients, Diabetologia 51 (2008) 1893-1900.
6. D.J. Cuthbertson, J.A. Babraj, K.J.W. Mustard, M.C. Towler, K.A. Green, H. Wackerhage, G.P. Leese, K. Baar, M. Thomason-Hughes, C. Sutherland, D.G. Hardie, M.J. Rennie, 5-Aminoimidazole-4-carboxamide-1-b-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men, Diabetes 56 (2007) 2078-2084.
7. C.M. Hasenour, D.E. Ridley, C.C. Hughey, F.D. James, E.P. Donahue, J. Shearer, B. Viollet, M. Foretz, D.H. Wasserman, 5-Aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR) effect on glucose production, but not energy metabolism, is independent of hepatic AMPK in vivo, J. Biol. Chem. 289 (2014) 5950-5959.
8. B. Guigas, K. Sakamoto, N. Taleux, S.M. Reyna, N. Musi, B. Viollet, L. Hue, Beyond AICA riboside: in search of new specific AMP-activated protein kinase activators, IUBMB Life 61 (2009) 18-26.
9. B. Daignan-Fornier, B. Pinson, 5-Aminoimidazole-4-carboxamide-1-b-Dribofuranosyl 50-monophosphate (AICAR), a highly conserved purine intermediate with multiple effects, Metabolites 2 (2012) 292-302 (and ref. therein).
10. I.K. Sebhat, R.W. Myers, AMPK activation in health and disease, in: M.C. Desai (Ed.), Annual Reports in Medicinal Chemistry, vol. 47, Academic Press, 2012, pp. 143-157.
11. E. Van Den Neste, G. Van den Berghe, F. Bontemps, AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies, Expert Opin. Investig. Drugs 19 (2010) 571-578 (and ref. therein).
12. R. Rattan, S. Giri, A.K. Singh, I. Singh, 5-Aminoimidazole-4-carboxamide-1-b-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase, J. Biol. Chem. 280 (2005) 39582-39593.
13. C. Campas, A.F. Santidrian, A. Domingo, J. Gil, Acadesine induces apoptosis in B cells from mantle cell lymphoma and splenic marginal zone lymphoma, Leukemia 19 (2005) 292-294.
14. C. Campas, J.M. Lopez, A.F. Santidrian, M. Barragan, B. Bellosillo, D. Colomer, J. Gil, Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes, Blood 101 (2003) 3674-3680.
15. Advancell, Acadra® (ATH001; acadesine) for chronic lymphocytic leukemia (CLL) and other limphoproliferative disorders, http://www.advancell.net/?page-id=92.
16. E. Van Den Neste, B. Cazin, A. Janssens, E. Gonzalez-Barca, M.J. Terol, V. Levy, J.P. de Oteyza, P. Zachee, A. Saunders, M. de Frias, C. Campas, Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study, Cancer Chemother. Pharmacol. 71 (2013) 581-591.
17. M. Meli, M. Pennati, M. Curto, M.G. Daidone, J. Plescia, S. Toba, D.C. Altieri, N. Zaffaroni, G. Colombo, Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead, J. Med. Chem. 49 (2006) 7721-7730.
18. A. Bracci, G. Colombo, F. Ronchetti, F. Compostella, 20-O-Alkyl-derivatives and 50-analogues of 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR) as potential Hsp90 inhibitors, Eur. J. Org. Chem. (2009) 5913-5919.
19. H. Ishikawa, Mizoribine and mycophenolate mofetil, Curr. Med. Chem. 6 (1999) 575-597 (and ref. therein).
20. Y. Kawasaki, Mizoribine: a new approach in the treatment of renal disease, Clin. Dev. Immunol. (2009), http://dx.doi.org/10.1155/2009/681482.
21. H.V. Kalluri, K.L. Hardinger, Current state of renal transplant immunosuppression: present and future, World J. Transpl. 2 (2012) 51-68.
22. V. Nair, Q. Shu, Inosine monophosphate dehydrogenase as a probe in antiviral drug discovery, Antivir. Chem. Chemother. 18 (2007) 245-258.
23. L. Hedstrom, IMP dehydrogenase: mechanism of action and inhibition, Curr. Med. Chem. 6 (1999) 545-560.
24. L. Gan, M.R. Seyedsayamdost, S. Shuto, A. Matsuda, G.A. Petsko, L. Hedstrom, The immunosuppressive agent mizoribine monophosphate forms a transition state analogue complex with inosine monophosphate dehydrogenase, Biochemistry 42 (2003) 857-863.
25. L.A. Turka, J. Dayton, G. Sinclair, C.B. Thompson, B.S. Mitchell, Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine, J. Clin. Invest. 87 (1991) 940-948.
26. D. Stypinski, M. Obaidi, M. Combs, M. Weber, A.J. Stewart, H. Ishikawa, Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers, Br. J. Clin. Pharmacol. 63 (2007) 459-468.
27. F. Picard-Jean, I. Bougie, S. Shuto, M. Bisaillon, The immunosuppressive agent mizoribine monophosphate is an inhibitor of the human RNA capping enzyme, PLoS ONE 8 (2013) e54621, http://dx.doi.org/10.1371/journal.pone.0054621.
28. R. Petrelli, P. Vita, I. Torquati, K. Felczak, D.J. Wilson, P. Franchetti, L. Cappellacci, Novel inhibitors of inosine monophosphate dehydrogenase in patent literature of the last decade, Recent Pat. Anticancer Drug Discov. 8 (2013) 103-125 (and ref. therein).
29. Y. Kosugi, Y. Saito, S. Mori, J. Watanabe, M. Baba, S. Shigeta, Antiviral activities of mizoribine and other inosine monophosphate dehydrogenase inhibitors against several ortho-and paramyxoviruses, Antivir. Chem. Chemother. 5 (1994) 366-371.
30. K. Yanagida, C. Baba, M. Baba, Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: synergistic effect of combination with interferon-a, Antivir. Res. 64 (2004) 195-201.
31. K. Naka, M. Ikeda, K. Abe, H. Dansako, N. Kato, Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-a, Biochem. Biophys. Res. Commun. 330 (2005) 871-879.
32. T. Kuramoto, T. Daikoku, Y. Yoshida, M. Takemoto, K. Oshima, Y. Eizuru, Y. Kanda, T. Miyawaki, K. Shiraki, Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir, J. Pharmacol. Exp. Ther. 333 (2010) 816-821.
33. N. Yoshimura, H. Ushigome, K. Akioka, S. Nobori, T. Suzuki, K. Sakai, M. Okamoto, The beneficial effect of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids on CMV infection in renal transplant recipients, Clin. Exp. Nephrol. 17 (2013) 127-133.
34. S. Pancheva, D. Dundarova, M. Remichkova, Potentiating effect of mizoribine on the anti-herpes virus activity of acyclovir, Z. Naturforsch. 57c (2002) 902-904.
35. V. Nair, F. Zhang, Synthesis of a novel carbocyclic analog of bredinin, Molecules 18 (2013) 11576-11585.
36. P. Franchetti, M. Pasqualini, L. Cappellacci, R. Petrelli, P. Vita, M. Grifantini, H.N. Jayaram, Ribose modified mizoribine analogues: synthesis and biological evaluation, Nucl. Nucl. Nucleic Acids 24 (2005) 2023-2027.
37. C. Barillari, N. Brown, Classical bioisosteres, in: R. Mannhold, H. Kubinyi, G. Folkers (Eds.), Methods and Principles in Medicinal Chemistry, in: N. Brown (Ed.), Bioisosteres in Medicinal Chemistry, vol. 54, Wiley-VCH, Weinheim, Germany, 2012, pp. 15-29.
38. L. Moreira Lima, E.J. Barreiro, Bioisosterism: a useful strategy for molecular modification and drug design, Curr. Med. Chem. 12 (2005) 23-49.
39. R.W. Sidwell, J.H. Huffman, G.P. Khare, L.B. Allen, J.T. Witkowski, R.K. Robins, Broad - spectrum antiviral activity of Virazole: 1-b-D-ribofuranosyl-1,2,4-triazole-3-caboxamide, Science 177 (1972) 705-706.
40. E. De Clercq, Another ten stories in antiviral drug discovery (part C): "old" and "new" antivirals, strategies, and perspectives, Med. Res. Rev. 29 (2009) 611-636 (and ref. therein).
41. S. Brillanti, G. Mazzella, E. Roda, Ribavirin for chronic hepatitis C: and the mystery goes on, Dig. Liver Dis. 43 (2011) 425-430.
42. J.B. McCormick, I.J. King, P.A. Webb, C.L. Scribner, B.B. Craven, K.M. Johnson, L.H. Elliot, R. Belmont-Williams, Lassa fever. Effective therapy with ribavirin, N. Engl. J. Med. 314 (1986) 20-26.
43. J.C. de la Torre, Reverse genetics approaches to combat pathogenic arenaviruses, Antivir. Res. 80 (2008) 239-255 (and ref. therein).
44. H. Moreno, A. Grande-Perez, E. Domingo, V. Martín, Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions, Viruses 4 (2012) 2786-2805.
45. E. Vela, Animal models, prophylaxis and therapeutics for arenavirus infections, Viruses 4 (2012) 1802-1829.
46. J.W. Huggins, Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug, Rev. Infect. Dis. 11 (Suppl. 4) (1989) 8750-8761.
47. T. Manigold, P. Vial, Human hantavirus infections: epidemiology, clinical features, pathogenesis and immunology, Swiss Med. Wkly. 144 (2014) w13937.
48. J.W. Huggins, C.M. Hsiang, T.M. Cosgriff, M.Y. Guang, J.I. Smith, Z.O. Wu, J.W. LeDuc, Z.M. Zheng, J.M. Meegan, Q.N. Wang, D.D. Oland, X.E. Gui, P.H. Gibbs, G.H. Yuan, T.M. Zhang, Prospective double-blind, concurrent, placebo controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome, J. Infect. Dis. 164 (1991) 1119-1127.
49. J.M. Rusnak, W.R. Byrne, K.N. Chung, P.H. Gibbs, T.T. Kim, E.F. Boudreau, T. Cosgriff, P. Pittman, K.Y. Kim, M.S. Erlichman, D.F. Rezvani, J.W. Huggins, Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea, Antivir. Res. 81 (2009) 68-76.
50. G.J. Mertz, L. Miedzinski, D. Goade, A.T. Pavia, B. Hjelle, C.O. Hansbarger, H. Levy, F.T. Koster, K. Baum, A. Lindemulder, W. Wang, L. Riser, H. Fernandez, R.J. Whitley, Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America, Clin. Infect. Dis. 39 (2004) 1307-1313.
51. D. Safronetz, E. Haddock, F. Feldmann, H. Ebihara, H. Feldmann, In vitro and in vivo activity of ribavirin against Andes Virus infection, PloS ONE 6 (2011) e23560.
52. M. Ogg, C.B. Jonsson, J.V. Camp, J.W. Hooper, Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome - after intranasal exposure to Andes Virus, Viruses 5 (2013) 2704-2720.
53. D.A. Bente, N.L. Forrester, D.M.Watts, A.J. McAuley, C.A. Whitehouse, M. Bray, Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity, Antivir. Res. 100 (2013) 159-189.
54. S. Ascioglu, H. Leblebicioglu, H. Vahaboglu, K.A. Chan, Ribavirin for patients with Crimean-Congo hemorrhagic fever: a systematic review and metaanalysis, J. Antimicrob. Chemother. 66 (2011) 1215-1222.
55. O. Ergonul, Treatment of Crimean-Congo hemorrhagic fever, Antivir. Res. 78 (2008) 125-131.
56. B. Dokuzoguz, A.K. Celikbas, S.E. Gok, N. Baykam, M.N. Eroglu, O. Ergonul, Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality, Clin. Infect. Dis. 57 (2013) 1270-1274.
57. C. Reed, K. Lin, C. Wilhelmsen, B. Friedrich, A. Nalca, A. Keeney, G. Donnelly, J. Shamblin, L.E. Hensley, G. Olinger, D.R. Smith, Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development, PLoS Negl. Trop. Dis. 7 (2013) e2156.
58. E. De Clercq, Antivirals: past, present and future, Biochem. Pharmacol. 85 (2013) 727-744.
59. J.D. Graci, C.E. Cameron, Mechanisms of action of ribavirin against distinct viruses, Rev. Med. Virol. 16 (2006) 37-48 (and ref. therein).
60. E. Thomas, M.G. Ghany, T.J. Liang, The application and mechanism of action of ribavirin in therapy of hepatitis C, Antivir. Chem. Chemother. 23 (2012) 1-12.
61. S. Beaucourt, M. Vignuzzi, Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance, Curr. Opin. Virol. 8 (2014) 10-15.
62. D.G. Streeter, J.T. Witkowski, G.P. Khare, R.W. Sidwell, R.J. Bauer, R.K. Robins, L.N. Simon, Mechanism of action of 1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent, Proc. Natl. Acad. Sci. U. S. A. 70 (1973) 1174-1178.
63. P. Leyssen, J. Balzarini, E. De Clercq, J. Neyts, The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase, J. Virol. 79 (2005) 1943-1947.
64. D.F. Smee, M. Bray, J.W. Huggins, Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro, Antivir. Chem. Chemother. 12 (2001) 327-335.
65. Y. Debing, S.U. Emerson, Y. Wang, Q. Pan, J. Balzarini, K. Dallmeier, J. Neyts, Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon, Antimicrob. Agents Chemother. 58 (2014) 267-273.
66. B. Langhans, H.D. Nischalke, S. Arndt, I. Braunschweiger, J. Nattermann, T. Cauerbruch, U. Spengler, Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C, PLoS ONE 7 (2012) e42094.
67. Y. Sun, D.H. Chung, Y.K. Chu, C.B. Jonsson, W.B. Parker, Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5-triphosphate, not with inhibition of IMP dehydrogenase, Antimicrob. Agents Chemother. 50 (2007) 84-88 (and ref. therein).
68. B. Eriksson, E. Helgstrand, N.G. Johansson, A. Larsson, A. Misiorny, J.O. Noren, L. Philipson, K. Stenberg, G. Stening, S. Stridh, et al., Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate, Antimicrob. Agents Chemother. 11 (1977) 946-951.
69. R. Fernandez-Larsson, K. O'Connell, E. Koumans, J.L. Paterson, Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction, Antimicrob. Agents Chemother. 33 (1989) 1668-1673.
70. R. Fernandez-Larsson, J.L. Paterson, Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase, Mol. Pharmacol. 38 (1990) 766-770.
71. S. Crotty, D. Maag, J.J. Arnold, W. Zhong, J.Y.N. Lau, Z. Hong, R. Andino, C.E. Cameron, The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen, Nat. Med. 6 (2000) 1375-1379.
72. S. Crotty, C.E. Cameron, R. Andino, RNA virus error catastrophe: direct molecular test by using ribavirin, Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6895-6900.
73. R.E. Lanford, D. Chavez, B. Guerra, J.Y.N. Lau, Z. Hong, K.M. Brasky, B. Beames, Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes, J. Virol. 75 (2001) 8074-8081.
74. A.M. Contreras, Y. Hiasa, W. He, A. Terella, E.V. Schmidt, R.T. Chung, Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system, J. Virol. 76 (2002) 8505-8517.
75. A.M. Ortega-Prieto, J. Sheldon, A. Grande-Perez, H. Tejero, J. Gregori, J. Quer, J.I. Esteban, E. Domingo, C. Perales, Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis, PLoS ONE 8 (2013) e71039.
76. W.E. Severson, C.S. Schmaljohn, A. Javadian, C.B. Jonsson, Ribavirin causes error catastrophe during Hantaan virus replication, J. Virol. 77 (2003) 481-488.
77. D.H. Chung, A. Vastermark, J.V. Camp, R. McAllister, S.K. Remold, Y.K. Chu, C. Bruder, C.B. Jonsson, The murine model for Hantaan virus-induced lethal disease shows two distinct paths in viral evolutionary trajectory with and without ribavirin treatment, J. Virol. 87 (2013) 10997-11007.
78. C.W. Day, D.F. Smee, J.G. Julander, V.F. Yamshchikov, R.W. Sidwell, J.D. Morrey, Error-prone replication of West Nile virus caused by ribavirin, Antivir. Res. 67 (2005) 38-45.
79. N.R. Shah, A. Sunderland, V.Z. Grdzelishvili, Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin, PLoS ONE 5 (2010) e11265.
80. C. Koh, T.J. Liang, What is the future of ribavirin therapy for hepatitis C? Antivir. Res. 104 (2014) 34-39 (and ref. therein).
81. M. Venegas, J. Brahm, R.A. Villanueva, Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment, Ann. Hepatol. 11 (2012) 827-837.
82. V. Conteduca, D. Sansonno, S. Russi, F. Pavone, F. Dammacco, Therapy of chronic hepatitis C virus infection in the era of direct-acting and hosttargeting antiviral agents, J. Infect. 68 (2014) 1-20 (and ref. therein).
83. E. De Clercq, Current race in the development of DAAs (direct-acting antivirals) against HCV, Biochem. Pharmacol. 89 (2014) 441-452.
84. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376449.htm.
85. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377888.htm.
86. C.M. Rice, M. Saeed, Treatment triumphs, Nature 510 (2014) 43-44.
87. M.J. Sofia, Nucleotide prodrugs for the treatment of HCV infection, in: S.J. Enna (Ed.), Advances in Pharmacology, Antiviral Agents, 67, Academic Press, Burlington, 2013, pp. 39-73.
88. J.-M. Pawlotsky, Hepatitis C virus: standard-of-care treatment, in: S.J. Enna (Ed.), Advances in Pharmacology, Antiviral Agents, 67, Academic Press, Burlington, 2013, pp. 169-215.
89. J.J. Feld, K.V. Kowdley, E. Coakley, S. Sigal, D.R. Nelson, D. Crawford, O. Weiland, H. Aguilar, J. Xiong, T. Pilot-Matias, B. DaSilva-Tillmann, L. Larsen, T. Podsadecki, B. Bernstein, Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin, N. Engl. J. Med. 370 (2014) 1594-1603.
90. K.V. Kowdley, E. Lawitz, F. Poordad, D.E. Cohen, D.R. Nelson, S. Zeuzem, G.T. Everson, P. Kwo, G.R. Foster, M.S. Sulkowski, W. Xie, T. Pilot-Matias, G. Liossis, L. Larsen, A. Khatri, T. Podsadecki, B. Bernstein, Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1, N. Engl. J. Med. 370 (2014) 222-232.
91. K.V. Kowdley, S.C. Gordon, K.R. Reddy, L. Rossaro, D.E. Bernstein, E. Lawitz, M.L. Shiffman, E. Schiff, R. Ghalib, M. Ryan, V. Rustgi, M. Chojkier, R. Herring, A.M. Di Bisceglie, P.J. Pockros, G.M. Subramanian, D. An, E. Svarovskaia, R.H. Hyland, P.S. Pang, W.T. Symonds, J.G. McHutchison, A.J. Muir, D. Pound, M.W. Fried, ION-3 investigators, ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis, N. Engl. J. Med. 370 (2014) 1879-1888.
92. N. Afdhal, K.R. Reddy, D.R. Nelson, E. Lawitz, S.C. Gordon, E. Schiff, R. Nahass, R. Ghalib, N. Gitlin, R. Herring, J. Lalezari, Z.H. Younes, P.J. Pockros, A.M. Di Bisceglie, S. Arora, G.M. Subramanian, Y. Zhu, H. Dvory-Sobol, J.C. Yang, P.S. Pang, W.T. Symonds, J.G. McHutchison, A.J. Muir, M. Sulkowski, P. Kwo, ION-2 investigators, ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection, N. Engl. J. Med. 370 (2014) 1483-1493.
93. N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin, M. Puoti, M. Romero-Gomez, J.P. Zarski, K. Agarwal, P. Buggisch, G.R. Foster, N. Brau, M. Buti, I.M. Jacobson, G.M. Subramanian, X. Ding, H. Mo, J.C. Yang, P.S. Pang, W.T. Symonds, J.G. McHutchison, A.J. Muir, A. Mangia, P. Marcellin, ION-1 Investigators, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N. Engl. J. Med. 370 (2014) 1889-1898.
94. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, I. Jacobson, E. Lawitz, A.S. Lok, F. Hinestrosa, P.J. Thuluvath, H. Schwartz, D.R. Nelson, G.T. Everson, T. Eley, M. Wind-Rotolo, S.P. Huang, M. Gao, D. Hernandez, F. McPhee, D. Sherman, R. Hindes, W. Symonds, C. Pasquinelli, D.M. Grasela, A1444040 Study Group, Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection, N. Engl. J. Med. 370 (2014) 211-221.
95. S. Zeuzem, G.M. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, R.H. Hyland, A. Illeperuma, E. Svarovskaia, D.M. Brainard, W.T. Symonds, G.M. Subramanian, J.G. McHutchison, O. Weiland, H.W. Reesink, P. Ferenci, C. Hezode, R. Esteban, VALENCE Investigators, Sofosbuvir and ribavirin in HCV genotypes 2 and 3, N. Engl. J. Med. 370 (2014) 1993-2001.
96. J.Z. Wu, H.Walker, J.Y.N. Lau, Z. Hong, Activation and deactivation of a broadspectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions, Antimicrob. Agents Chemother. 47 (2003) 426-431.
97. P. Marcellin, R.G. Gish, N. Gitlin, J. Heise, D.G. Halliman, E. Chun, M. Rodriguez-Torres, Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients, J. Hepatol. 52 (2010) 32-38.
98. M.B.L. Kryger, B.M. Wohl, A.A.A. Smith, A.N. Zelikin, Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug, Chem. Commun. 49 (2013) 2643-2645.
99. E.F. Craparo, D. Triolo, G. Pitarresi, G. Giammona, G. Cavallaro, Galactosylated micelles for a ribavirin prodrug targeting to hepatocytes, Biomacromolecules 14 (2013) 1838-1849.
100. K.L.B. Borden, B. Culjkovic-Kraljacic, Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? Leuk. Lymphoma 51 (2010) 1805-1815 (and ref. therein).
101. K. Borden, H. Zahreddine, B. Culjkovic-Kraljacic, Combination therapy using ribavirin as eif4e inhibitor, Patent WO 2013037043 A1, 2013.
102. N. Minakawa, T. Takeda, T. Sasaki, A. Matsuda, T. Ueda, Nucleosides and nucleotides. 96. Synthesis and antitumor activity of 5-ethynyl-1-b-D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives, J. Med. Chem. 34 (1991) 778-786.
103. N. Minakawa, A. Matsuda, Mechanism-based design of inosine 50-monophosphate dehydrogenase inhibitors: synthesis and biological activities of 5-ethynyl-1-b-D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives, Curr. Med. Chem. 6 (1999) 615-628.
104. N. Minakawa, N. Kojima, T. Sasaki, A. Matsuda, Nucleosides and nucleotides. 140. Synthesis and antileukemic activity of 5-carbon-substituted 1-b-Dribofuranosylimidazole-4-carboxamides, Nucl. Nucl. 15 (1996) 251-263.
105. E. De Clercq, M. Cools, J. Balzarini, R. Snoeck, G. Andrei, M. Hosoya, S. Shigeta, T. Ueda, N. Minakawa, A. Matsuda, Antiviral activities of 5-ethynyl-1-b-Dribofuranosylimidazole-4-carboxamide and related compounds, Antimicrob. Agents Chemother. 35 (1991) 679-684.
106. S. Shigeta, S. Mori, M. Baba, M. Ito, K. Honzumi, K. Nakamura, H. Oshitani, Y. Numazaki, A. Matsuda, T. Obara, S. Shuto, E. De Clercq, Antiviral activities of ribavirin, 5-ethynyl-1-b-D-ribofuranosylimidazole-4-carboxamide, and 60-(R)-60-C-methylneplanocin A against several ortho-and paramyxoviruses, Antimicrob. Agents Chemother. 36 (1992) 435-439.
107. J. Balzarini, A. Karlsson, L. Wang, C. Bohman, K. Horska, I. Votruba, A. Fridland, A. Van Aerschot, P. Herdewijn, E. De Clercq, EICAR (5-ethynyl-1-b-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis, J. Biol. Chem. 268 (1993) 24591-24598.
108. W. Wang, V.V. Papow, N. Minakawa, A. Matsuda, K. Biemann, L. Hedstrom, Inactivation of inosine 50-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-b-D-ribofuranosylimidazole-4-carboxamide 50-monophosphate, Biochemistry 35 (1996) 95-101.
109. M. Jashes, M. Gonzalez, M. Lopez-Lastra, E. De Clercq, A. Sandino, Inhibitors of infectious pancreatic necrosis virus (IPNV) replication, Antivir. Res. 29 (1996) 309-312.
110. M. Jashes, G. Mlynarz, E. De Clercq, A.M. Sandino, Inhibitory effects of EICAR on infectious pancreatic necrosis virus replication, Antivir. Res. 45 (2000) 9-17.
111. F. Dal Pozzo, V. Galligioni, F. Vaccari, L. Gallina, M. Battilani, A. Scagliarini, Antiviral efficacy of EICAR against canine distemper virus (CDV) in vitro, Res. Vet. Sci. 88 (2010) 339-344.
112. G.R. Revankar, V.C. Solan, R.K. Robins, J.T. Witkowski, Synthesis and biological activity of certain 1,2,3-triazole carboxamide nucleosides related to bredinin and pyrazofurin, Nucl. Acids Res. Symp. Ser. 9 (1981) 65-68.
113. K. El Akri, K. Bougrin, J. Balzarini, A. Faraj, R. Benhida, Efficient synthesis and in vitro cytostatic activity of 4-substituted triazolyl-nucleosides, Bioorg. Med. Chem. Lett. 17 (2007) 6656-6659.
114. T. Ostrowski, P. Januszczyk, M. Cieslak, J. Kazmierczak-Baranska, B. Nawrot, E. Bartoszak-Adamska, J. Zeidler, 5-Ethynyl-1-b-D-ribofuranosyl-1H-[1,2,3] triazole-4-carboxylic acid amide (ETCAR) and its analogues: synthesis and cytotoxic properties, Bioorg. Med. Chem. 19 (2011) 4386-4398.
115. A. Krajczyk, K. Kulinska, T. Kulinski, B.L. Hurst, C.W. Day, D.F. Smee, T. Ostrowski, P. Januszczyk, J. Zeidler, Antivirally active ribavirin analogues - 4,5-disubstituted 1,2,3-triazole nucleosides: biological evaluation against certain respiratory viruses and computational modelling, Antivir. Chem. Chemother. 23 (2014) 161-171.
116. R. Alvarez, S. Velazquez, A. San-Felix, S. Aquaro, E. De Clercq, C.-F. Perno, A. Karlsson, J. Balzarini, M.J. Camarasa, 1,2,3-Triazole-[20,50-bis-O-(tertbutyldimethylsilyl)-b-D-ribofuranosyl]-30-spiro-500-(400-amino-100,200-oxathiole 200,200-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity, J. Med. Chem. 37 (1994) 4185-4194.
117. S. Velazquez, R. Alvarez, C. Perez, F. Gago, E. De Clercq, J. Balzarini, M.-J. Camarasa, Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues, Antivir. Chem. Chemother. 9 (1998) 481-489.
118. J.H. Cho, D.L. Bernard, R.W. Sidwell, E.R. Kern, C.K. Chu, Synthesis of cyclopentenyl carbocyclic nucleosides as potential antiviral agents against orthopoxviruses and SARS, J. Med. Chem. 49 (2006) 1140-1148.
119. Y. Saito, V. Escuret, D. Durantel, F. Zoulim, R.F. Schinazi, L.A. Agrofoglio, Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon, Bioorg. Med. Chem. 11 (2003) 3633-3639.
120. N. Joubert, R.F. Schinazi, L.A. Agrofoglio, Efficient Pd(0)-catalyzed synthesis of 1,2,3-triazolo-30-deoxycarbanucleosides and their analogues, Tetrahedron 61 (2005) 11744-11750.
121. S. Radi, H.B. Lazrek, Synthesis and biological activity of new 1,2,3-triazole acyclonucleosides analogues of ACV, J. Chem. Res. (S) (2002) 264-266.
122. M. Driowya, A. Puissant, G. Robert, P. Auberger, R. Benhida, K. Bougrin, Ultrasound-assisted one-pot synthesis of anti-CML nucleosides featuring 1,2,3-triazole nucleobase under iron-copper catalysis, Ultrason. Sonochemistry 19 (2012) 1132-1138.
123. M.G. Ferreira, L.C.S. Pinheiro, O.A. Santos-Filho, M.D.S. Pecanha, C.Q. Sacramento, V. Machado, V.F. Ferreira, T.M.L. Souza, N. Boechat, Design, synthesis, and antiviral activity of new 1H-1,2,3-triazole nucleoside ribavirin analogs, Med. Chem. Res. 23 (2014) 1501-1511.
124. R. Zhu, M. Wang, Y. Xia, F. Qu, J. Neyts, L. Peng, Arylethynyltriazole acyclonucleosides inhibit hepatitis C virus replication, Bioorg. Med. Chem. Lett. 18 (2008) 3321-3327.
125. J. Wan, Y. Xia, Y. Liu, M. Wang, P. Rocchi, J. Yao, F. Qu, J. Neyts, J.L. Iovanna, L. Peng, Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity, J. Med. Chem. 52 (2009) 1144-1155.
126. M. Wang, Y. Xia, Y. Fan, P. Rocchi, F. Qu, J.L. Iovanna, L. Peng, A novel arylethynyltriazole acyclonucleoside inhibits proliferation of drug-resistant pancreatic cancer cells, Bioorg. Med. Chem. Lett. 20 (2010) 5979-5983.
127. Y. Xia, M. Wang, O. Demaria, J. Tang, P. Rocchi, F. Qu, J.L. Iovanna, L. Alexopoulou, L. Peng, A novel bitriazolyl acyclonucleoside endowed with dual antiproliferative and immunomodulatory activity, J. Med. Chem. 55 (2012) 5642-5646.
128. Y. Xia, Y. Liu, J. Wan, M. Wang, P. Rocchi, F. Qu, J.L. Iovanna, L. Peng, Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer, J. Med. Chem. 52 (2009) 6083-6096.
129. Y. Xia, Y. Liu, P. Rocchi, M. Wang, Y. Fan, F. Qu, J.L. Iovanna, L. Peng, Targeting heat shock factor 1 with a triazole nucleoside analog to elicit potent anticancer activity on drug-resistant pancreatic cancer, Cancer Lett. 318 (2012) 145-153.
130. D.-H. Chung, S.C. Kumarapperuma, Y. Sun, Q. Li, Y.-K. Chu, J.B. Arterburn, W.B. Parker, J. Smith, K. Spik, H.N. Ramanathan, C.S. Schmaljohn, C.B. Jonsson, Synthesis of 1-b-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus, Antivir. Res. 79 (2008) 19-27.
131. M. McDowell, S.R. Gonzales, S.C. Kumarapperuma, M. Jeselnik, J.B. Arterburn, K.A. Hanley, A novel nucleoside analog, 1-b-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR), exhibits efficacy against a broad range of flaviviruses in vitro, Antivir. Res. 87 (2010) 78-80.